Onivyde for Metastatic Pancreatic Cancer (Closed)


( Last Updated : December 2, 2016)
Generic Name:
Nanoliposomal Irinotecan
Project Status:
Cancelled
Manufacturer:
Baxalta Canada Corporation
Brand Name:
Onivyde
Project Line:
Reimbursement Review
Project Number:
PC0096-000

Details


Tumour Type:
Gastrointestinal
Indications:
Metastatic Pancreatic Cancer
Funding Request:
For second-line treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin in adult patients who have been previously treated with gemcitabine-based therapy
Pre Noc Submission:
Yes
Sponsor:
Baxalta Canada Corporation
Clarification:
The submitter notified pCODR that they will not be filing the submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.